Literature DB >> 17371460

Modulation of glucocorticoid metabolism by the growth hormone - IGF-1 axis.

Amar Agha1, John P Monson.   

Abstract

The growth hormone-insulin-like growth factor 1 (GH-IGF-1) axis plays an important role in modulating the peripheral metabolism of glucocorticoids mainly through its effect on the isoenzyme 11 beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1) which, in vivo, functions as a reductase catalysing the conversion of cortisone to cortisol. Several in vivo and ex vivo studies have shown that the GH-IGF-I system inhibits the expression and activity of 11beta-HSD1 in adipose tissues and the liver resulting in reduced local regeneration of cortisol. This interaction has clinically significant implications as it may at least partly explain the phenotypes of acromegaly and adult GH deficiency and the effects that treatment of these conditions has on body composition. In addition, by accelerating the peripheral metabolism of cortisol, GH therapy may precipitate adrenal insufficiency in susceptible hypopituitary patients, and endocrinologists should be mindful of this phenomenon when starting hypopituitary patients on GH replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371460     DOI: 10.1111/j.1365-2265.2007.02763.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  26 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Growth hormone deficiency in patients with obesity.

Authors:  Roberto Salvatori
Journal:  Endocrine       Date:  2015-03-10       Impact factor: 3.633

3.  Improved adipose tissue metabolism after 5-year growth hormone replacement therapy in growth hormone deficient adults: The role of zinc-α2-glycoprotein.

Authors:  Miroslav Balaž; Barbara Ukropcova; Timea Kurdiova; Miroslav Vlcek; Martina Surova; Patrik Krumpolec; Peter Vanuga; Daniela Gašperíková; Iwar Klimeš; Juraj Payer; Christian Wolfrum; Jozef Ukropec
Journal:  Adipocyte       Date:  2014-12-17       Impact factor: 4.534

4.  Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study.

Authors:  Chris Yedinak; Nadia Hameed; Marika Gassner; Jessica Brzana; Shirley McCartney; Maria Fleseriu
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 5.  Glucocorticoids and the regulation of growth hormone secretion.

Authors:  Gherardo Mazziotti; Andrea Giustina
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

Review 6.  Pituitary disease mortality: is it fiction?

Authors:  Eva Marie Erfurth; Peter Siesjö; Thomas Björk-Eriksson
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

7.  Relative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls.

Authors:  M Russell; M Bredella; P Tsai; N Mendes; K K Miller; A Klibanski; M Misra
Journal:  J Clin Endocrinol Metab       Date:  2009-05-12       Impact factor: 5.958

Review 8.  WONOEP appraisal: Molecular and cellular biomarkers for epilepsy.

Authors:  Lauren E Walker; Damir Janigro; Uwe Heinemann; Raili Riikonen; Christophe Bernard; Manisha Patel
Journal:  Epilepsia       Date:  2016-07-04       Impact factor: 5.864

9.  Glucocorticoids and neonatal brain injury: the hedgehog connection.

Authors:  Alberto Gulino; Enrico De Smaele; Elisabetta Ferretti
Journal:  J Clin Invest       Date:  2009-02       Impact factor: 14.808

10.  Lack of regulation of 11beta-hydroxysteroid dehydrogenase type 1 during short-term manipulation of GH in patients with hypopituitarism.

Authors:  Helga A Sigurjonsdottir; Ruth Andrew; Roland H Stimson; Gudmundur Johannsson; Brian R Walker
Journal:  Eur J Endocrinol       Date:  2009-06-23       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.